MedTech Dive March 27, 2024
William Blair analysts called the clearance a positive surprise, explaining that the FDA has denied several therapies in the patient population.
Dive Brief:
- Neuronetics received 510(k) clearance to use its transcranial magnetic stimulation (TMS) device to treat adolescents with major depressive disorder (MDD).
- The Food and Drug Administration expanded the label to cover people aged 15 to 21 years after Neuronetics shared real-world data linking its device to clinically meaningful improvements in the severity of depression in 78% of patients, according to the company’s Monday announcement.
- William Blair analysts called the clearance a positive surprise, explaining that the FDA has denied several therapies in the patient population. Neuronetics competes with Brainsway, Apollo TMS, Magstim, Magventure, CloudTMS and Nexstim for...
Today's Sponsors
Today's Sponsor